Abstract:294 Background: Gastric cancer patients with malignant ascites often have poor functional status and malnutrition that precludes receipt of systemic therapies. Thus, these patients have a very poor prognosis. Beginning in 2019, our multidisciplinary gastric cancer disease-oriented team implemented a more aggressive supportive care plan for gastric cancer patients with malignant ascites. The initiative included measures such as supplemental enteral nutrition, ascites drainage, and initiation of chemotherapy on an inpatient basis. We compared outcomes for gastric cancer patients who presented with synchronous malignant ascites treated before and after the implementation of the care plan. Methods: We performed a retrospective review of our institutional database to identify patients diagnosed with gastric adenocarcinoma and synchronous malignant ascites between 2010-2022. We compared survival between patients diagnosed from 2010-2018, which will be referred to as the historical control era and patients diagnosed from 2019-2022, which will be called the aggressive supportive care era. Results: 54 patients were included in our analysis; 31 patients were treated in the historical control time frame and 23 patients treated during the aggressive supportive care era. Demographic, clinical, and pathologic characteristics were similar between groups. 3% of historical controls received supplemental tube feeds at diagnosis as compared to 30% of the aggressive supportive care cohort (p=0.008). 3% of historical controls received their first cycle of chemotherapy in the inpatient setting versus 39% of patients treated during the aggressive supportive care era (p=0.001). The median number of chemotherapy cycles received was 5 among historical controls and 9.5 among aggressive supportive care era patients (p = 0.02). There was no difference in the number of days spent as an inpatient between the two groups. The median overall survival for historical control patients was 5.4 months as compared to 10.4 months for patients treated during aggressive supportive care era (p=0.035). Conclusions: Gastric cancer patients with synchronous malignant ascites treated during a timeframe when our multidisciplinary team implemented more aggressive supportive care measures had improved OS as compared to historic controls.Our results suggest that aggressive supportive measures for these patients with highly challenging clinical issues and poor prognosis can prolong survival. Specifically, initiation of chemotherapy in the inpatient setting and supplemental nutrition should be considered for patients at high risk for treatment intolerance.

Management of non-ovarian cancer malignant ascites through indwelling catheter drainage

Clinical Study of Intraperitoneal Injection Bevacizumab (BV) Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy (CT) in Treatment of Malignant Ascites of Ovarian Cancer (OC).

Ascites is a poor prognostic factor in advanced pancreatic adenocarcinoma and may be undertreated: a prospective cohort study

Clinical practice guidelines for the management of central venous catheter for critically ill patients

Percutaneous placement of Arrow catheter for palliation of refractory ascites

Application of Drainage with Central Venous Catheteriazation Set in Hepatic Cirrhosis Patients with Refractory Ascites

Intraperitoneal Administration of Cisplatin Plus Bevacizumab for the Management of Malignant Ascites in Ovarian Epithelial Cancer: Results of A Phase Iii Clinical Trial

Central venous pressure catheter for large-volume paracentesis in refractory ascites

Palliative long-term abdominal drains vs large volume paracenteses for the management of refractory ascites in end-stage liver disease

Retrospective Data about the Catheter-Related Complications and Management in Massive Bus Burn Casualties.

Association of intensifying supportive care with improved survival in patients with gastric cancer with malignant ascites.

Permanent indwelling peritoneal catheters for palliation of refractory ascites in end‐stage liver disease: A systematic review

Safety and Effectiveness of Central Vein Catheters Indwelling with Subcutaneous Port in Patients Undergoing Chemotherapy

Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies

Catheterization-associated Complications of Intraperitoneal Chemotherapy in Advanced Gastric Cancer

Progress in the treatment of malignant ascites

Recent developments in the management of ascites in cirrhosis

Early short-term abdominal paracentesis drainage in moderately severe and severe acute pancreatitis with pelvic ascites

Clinical efficacy and safety of percutaneous drainage for post-operative fluid collection in patients with bladder cancer undergoing radical cystectomy and urinary diversion

Innovative approaches to the management of ascites in cirrhosis

Predicting and managing intra-abdominal collections by image guided percutaneous drainage after cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.: A five-year experience with 1313 patients